Results 151 to 160 of about 39,591 (271)
Acta Ophthalmologica, Volume 104, Issue 4, Page e382-e396, June 2026.Abstract Purpose To evaluate long‐term outcomes of anti‐VEGF therapy for nAMD using the Polish Retinal Therapeutic Program Monitoring Registry. Methods The cohort consisted of 63 840 eyes with nAMD qualified for treatment from 2016 to 2022, with follow‐up through 31 October 2023. Long‐term follow‐up (>5 years) was conducted for 7631 eyes.
Sławomir Teper +9 more
wiley +1 more source
Acta Ophthalmologica, Volume 104, Issue 4, Page e406-e415, June 2026.Abstract Purpose This study characterized and assessed vision‐related quality of life (VRQoL) in patients with neovascular age‐related macular degeneration (nAMD) who discontinued treatment with intravitreal anti‐vascular endothelial growth factor (anti‐VEGF), comparing them to those undergoing treatment.
Noreddin Shekho +4 more
wiley +1 more source
Nursing &Health Sciences, Volume 28, Issue 2, June 2026.ABSTRACT Ophthalmic surgeries pose infection risks. Traditional control methods rely on manual monitoring, creating a need for more precise, data‐driven nursing models. This study evaluated the effectiveness of real‐time data analysis in improving ophthalmic infection prevention and control outcomes.
Zhenhui Chen +3 more
wiley +1 more source
Advanced Science, Volume 13, Issue 25, 4 May 2026.Lithium‐epigallocatechin gallate nanoparticles (Li‐EGCG NPs) are co‐transplanted with embryonic stem cell‐derived retinal ganglion cells (ESC‐RGCs) to enhance cell survival and therapeutic efficacy in an acute pathological glaucomatous injury model. This synergistic approach protects RGC cells, preserves retinal structure and improves visual function ...
Moxin Chen +14 more
wiley +1 more source
How to treat recurrences after Avastin treatment for neovascular AMD: stick to Avastin or switch to Lucentis? [PDF]
, 2008 Haritoglou, Christos +4 more
core +1 more source
Brain and Behavior, Volume 16, Issue 5, May 2026.Schematic summary of visual electrophysiology and retinal and brain pathology. The diagram integrates PVEP abnormalities, retinal pathology, and brain pathology in PFF‐injected mice. Based on behavioral outcomes, the three groups were categorized as control, prodromal PD, and PD, corresponding to the PBS, 3‐month PFF (3 MPI), and 6‐month PFF (6 MPI ...
Qin Zhang +7 more
wiley +1 more source
A Cationic Block Co‐Polymer for Gene Delivery in the Posterior Segment of the Eye
Journal of Biomedical Materials Research Part A, Volume 114, Issue 5, May 2026.ABSTRACT Diseases of the back of the eye such as neovascular age‐related macular degeneration (nAMD) are vision threatening and treatment is burdensome for patients, often requiring ocular injections every other month. Injection risks and logistics lower patient compliance; however, even patients receiving optimal treatment can deteriorate.
Amber Monteiro +8 more
wiley +1 more source
Small Science, Volume 6, Issue 5, May 2026.Aptamer‐functionalized nanocarriers represent a versatile platform for targeted therapy in bone and joint diseases. This review presents five complementary design strategies: free aptamers for soluble targets, bispecific multivalent constructs for enhanced avidity, nanoparticle‐conjugated aptamers for selective tissue accumulation, aptamer‐based ...
Hamdi Al‐Azzani +5 more
wiley +1 more source
Aging Cell, Volume 25, Issue 5, May 2026.A Bruchs membrane (BrM) mimic based on aged decellularized BrM was developed and differentially expressed proteins in aged dECM‐BrM that may provide specific biochemical cues fundamental to model AMD in vitro were identified. RPE culture on aged dECM‐BrM developed certain AMD‐like features including reduced TEER and expression of drusen components ...
Blanca Molins +8 more
wiley +1 more source
Acta Ophthalmologica, Volume 104, Issue 3, Page 296-304, May 2026.Abstract Purpose To evaluate visual, anatomical and safety outcomes of aflibercept 8 mg in previously treated patients with neovascular age‐related macular degeneration (nAMD). Methods This retrospective study included nAMD patients switched to aflibercept 8 mg from prior anti‐VEGF therapies at Sahlgrenska University Hospital between February 2024 and ...
Imadeddin Abu Ishkheidem +5 more
wiley +1 more source